Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in Interest ReceivablesFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Marker Therapeutics (MRKR) Change in Interest Receivables (2018 - 2025)

Marker Therapeutics (MRKR) has disclosed Change in Interest Receivables for 8 consecutive years, with -$9182.0 as the latest value for Q3 2025.

  • Quarterly Change in Interest Receivables rose 99.47% to -$9182.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $920743.0 through Sep 2025, up 39.28% year-over-year, with the annual reading at $1.3 million for FY2024, 195.98% up from the prior year.
  • Change in Interest Receivables for Q3 2025 was -$9182.0 at Marker Therapeutics, up from -$784430.0 in the prior quarter.
  • The five-year high for Change in Interest Receivables was $1.6 million in Q4 2024, with the low at -$1.7 million in Q3 2024.
  • Average Change in Interest Receivables over 5 years is $34978.6, with a median of $1948.0 recorded in 2022.
  • The sharpest move saw Change in Interest Receivables soared 12016516.67% in 2022, then crashed 67816.53% in 2023.
  • Over 5 years, Change in Interest Receivables stood at -$6.0 in 2021, then skyrocketed by 12016516.67% to $720985.0 in 2022, then soared by 31.0% to $944502.0 in 2023, then soared by 69.64% to $1.6 million in 2024, then crashed by 100.57% to -$9182.0 in 2025.
  • According to Business Quant data, Change in Interest Receivables over the past three periods came in at -$9182.0, -$784430.0, and $112062.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.